GlassScriptPhysician profile
Katie L Marks
NPI 1154596047
$7,237.32
in general payments reported to CMS, 2019-2025
26 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $490 · 2021: $853 · 2022: $1,296 · 2023: $1,307 · 2024: $934 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,948.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,658.79 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,351.77 | 2020-2025 | |
| Glaxosmithkline, LLC. | $665.13 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $626.12 | 2019-2025 | Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $329.65 | 2020-2025 | |
| Kaleo, INC. | $278.78 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $240.71 | 2019-2025 | Xembify |
| Optinose US, INC. | $234.35 | 2019-2025 | |
| Leo Pharma INC. | $214.77 | 2023-2025 | Anzupgo, Adbry |
| Genentech USA, INC. | $207.37 | 2019-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $195.42 | 2020-2023 | Takhzyro |
| Pfizer INC. | $189.08 | 2020-2022 | |
| Pharming Healthcare, INC. | $148.88 | 2019-2020 | |
| Alk-Abello, INC | $136.68 | 2020-2025 | Ragwitek, Grastek, Odactra |
| Csl Behring | $127.66 | 2019-2025 | Haegarda |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $122.93 | 2022-2025 | Opzelura |
| Aimmune Therapeutics, INC. | $108.29 | 2022 | |
| Shire North American Group INC | $83.80 | 2019 | |
| Biocryst US Sales Co., LLC | $76.92 | 2025 | Orladeyo |
| Galderma Laboratories, L.P. | $60.03 | 2025 | Nemluvio |
| Phadia US INC. | $49.40 | 2021-2023 | Immunocap |
| Bio Products Laboratory USA, INC. | $29.69 | 2021-2022 | |
| Amgen INC. | $28.25 | 2025 | Actimmune |
| Organon LLC | $25.61 | 2025 | Vtama |
| Horizon Therapeutics Plc | $25.15 | 2023 | Actimmune |
| Ars Pharmaceuticals Operations, INC. | $22.09 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Marks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.